Monitor for any Advance Notice under the Purchase Agreement indicating YA will draw down on the equity line — each draw adds selling pressure and dilutes existing holders.
Price Chart
Executive Summary
The SEC declared effective RedHill Biopharma's F-3 shelf registration (File No. 333-297223) on July 13, 2026. This enables the company to issue and sell securities, including up to 5,000,000 ADSs to YA II PN under an existing Standby Equity Purchase Agreement, creating potential dilution overhang. The F-3 becomes operative after an earlier F-1/A (filed January 2026) covering a separate equity line with YA, amplifying the company's ability to access capital.
Key Facts
- Effectiveness date: July 13, 2026
- Registration covers an F-3 shelf
- Up to 5,000,000 ADSs can be sold to YA II PN under the Purchase Agreement
- Earlier F-1/A (Jan 2026) covers up to 6,465,559 ADSs for the same selling shareholder
- Company has a $4M market cap and $1K insider selling in the last 30 days
Financial Impact
Potential dilution up to ~5M ADSs (each ADS = 10,000 ordinary shares) under the Purchase Agreement, with no price floor; proceeds to company up to $25M but at a discount to market (95-97% of VWAP).
Risk Factors
- Immediate dilutive overhang from the now-effective shelf registration
- Equity line pricing at a discount to VWAP (95-97%) creates persistent downward pressure
- Extremely small market cap (~$4M) amplifies price impact of any sell orders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002275 |
| Document: 9999999995-26-002275-index.html | 9999999995-26-002275 |
| Document: 9999999995-26-002275.txt | 9999999995-26-002275 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers